Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 150Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × B701 protein, Human herpesvirus 6 × Genitourinary × Clear all
NCT02925533 2017-06-27

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Dana-Farber Cancer Institute

Phase 1 Terminated
1 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡